Literature DB >> 17238195

The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.

Aditya A Wakankar1, Jun Liu, David Vandervelde, Y John Wang, Steven J Shire, Ronald T Borchardt.   

Abstract

The aspartate residue (Asp 32) located in the complementarity-determining region (CDR) of a recombinant humanized monoclonal antibody (MAb I) is highly susceptible to the isomerization reaction. The modification of Asp 32 residue due to the isomerization reaction results in a significant reduction in the binding affinity of MAb I to IgE. The binding of a MAb I therapeutic to IgE is important for its desired pharmacological effect. In earlier investigations, we demonstrated that the conformational flexibility and residue exposure are factors that are responsible for the observed reactivity of Asp 32 in MAb I. This report explores the role of cosolutes such as glycerol and sucrose in the modulation of Asp 32 reactivity in MAb I. These cosolutes are routinely incorporated in injectable pharmaceutical formulations. The reactivity of the Asp residue in MAb I in these different cosolute-based formulations was compared to its reactivity in a peptide model VDYDG comprising residues 29-33 of MAb I. The formulations of MAb I and VDYDG containing varying concentrations of glycerol and sucrose were incubated at 50 degrees C for a period of 5-7 days. The isomerization of the Asp residue in VDYDG and MAb I was monitored using rp-HPLC and hydrophobic interaction chromatography (HIC), respectively. Structural analysis of MAb I using differential scanning calorimetry (DSC) demonstrated that the structural stability of MAb I was increased in formulations containing glycerol and sucrose. However, the stability of Asp 32 in MAb I was significantly decreased in these formulations. This research suggests that a formulation approach that relies purely on enhancing the structural stability of proteins through addition of these cosolutes could result in problems associated with the chemical stability of these biomolecules. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17238195     DOI: 10.1002/jps.20823

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 2.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

3.  Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization.

Authors:  Joshua J Klaene; Wenqin Ni; Joshua F Alfaro; Zhaohui Sunny Zhou
Journal:  J Pharm Sci       Date:  2014-07-14       Impact factor: 3.534

Review 4.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

5.  Evaluation of the physical stability of the EC5 domain of E-cadherin: effects of pH, temperature, ionic strength, and disulfide bonds.

Authors:  Kai Zheng; C Russell Middaugh; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

6.  Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions.

Authors:  Jasmin F Sydow; Florian Lipsmeier; Vincent Larraillet; Maximiliane Hilger; Bjoern Mautz; Michael Mølhøj; Jan Kuentzer; Stefan Klostermann; Juergen Schoch; Hans R Voelger; Joerg T Regula; Patrick Cramer; Apollon Papadimitriou; Hubert Kettenberger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

7.  An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.

Authors:  Peipei Liu; Zhongzong Pan; Chunyin Gu; Xiaodan Cao; Xiaowu Liu; Jianjian Zhang; Zheng Xiao; Xueping Wang; Haibing Guo; Dianwen Ju; Su-Jun Deng
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

8.  Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies.

Authors:  Catherine M Eakin; Amanda Miller; Jennifer Kerr; James Kung; Alison Wallace
Journal:  Front Pharmacol       Date:  2014-04-29       Impact factor: 5.810

9.  Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.

Authors:  Devin Tesar; Jacob Luoma; Emily A Wyatt; Catherine Shi; Whitney Shatz; Philip E Hass; Mary Mathieu; Li Yi; Jacob E Corn; Katie F Maass; Kathryn Wang; Michelle Z Dion; Nisana Andersen; Kelly M Loyet; Menno van Lookeren Campagne; Karthikan Rajagopal; Leslie Dickmann; Justin M Scheer; Robert F Kelley
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

Review 10.  In silico prediction of post-translational modifications in therapeutic antibodies.

Authors:  Shabdita Vatsa
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.